Quick Answer
Taysha Gene Therapies, Inc. reported Operating Income of -$110.50 million for fiscal year 2025.
Taysha Gene Therapies, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$110.50M | -20.8% |
| 2024 | -$91.46M | -26.3% |
| 2023 | -$72.44M | +55.4% |
| 2022 | -$162.45M | +6.2% |
| 2021 | -$173.27M | -302.9% |
| 2020 | -$43.00M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$34.02M | -31.4% | -27.2% |
| June 30, 2025 | -$26.75M | -25.6% | -24.9% |
| March 31, 2025 | -$21.42M | +12.0% | +17.3% |
| September 30, 2024 | -$25.90M | -59.4% | -21.6% |
| June 30, 2024 | -$21.30M | +8.9% | +12.5% |
| March 31, 2024 | -$24.33M | -46.9% | -49.7% |
| September 30, 2023 | -$16.25M | +36.2% | +30.5% |
| June 30, 2023 | -$23.38M | +29.9% | -41.2% |
- Taysha Gene Therapies, Inc. showed a decrease of -20.8% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Taysha Gene Therapies, Inc.’s operating income has declined by 157.0% (from -$43.00 million to -$110.50 million).
- The most recent figure is from Taysha Gene Therapies, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: